Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression

The death receptor Fas (Apo1/CD95) and Fas ligand (FasL) system is recognised as a major pathway for the induction of apoptosis in vivo, and antiapoptosis via its blockade plays a critical role in carcinogenesis and progression in several malignancies. However, the function of Fas–FasL system in urothelial cancer (UC) has not been elucidated. We therefore investigated the expression of Fas, FasL and Decoy receptor 3 for FasL (DcR3) in UC specimens and cell lines, and examined the cytotoxic effect of an anti-Fas-activating monoclonal antibody (mAb) in vitro. Immunohistochemical examinations of Fas-related molecules were performed on 123 UC and 30 normal urothelium surgical specimens. Normal urothelium showed Fas staining in the cell membrane and cytoplasm. In UC, less frequent Fas expression was significantly associated with a higher pathological grade (P<0.0001), a more advanced stage (P=0.023) and poorer prognosis (P=0.010). Fas and the absence thereof were suggested to be crucial factors with which to select patients requiring more aggressive treatment. Moreover, low-dose anti-Fas-activating mAb sensitised resistant cells to adriamycin, and this synergistic effect could be applied in the development of new treatment strategy for UC patients with multidrug-resistant tumours.

[1]  R. Hurst,et al.  Bladder surface glycosaminoglycans: an epithelial permeability barrier. , 1990, The Journal of urology.

[2]  J. Ro,et al.  Cytologic and histologic features of superficial bladder cancer. , 1992, The Urologic clinics of North America.

[3]  M. Weller,et al.  Local Fas/APO‐1 (CD95) ligand‐mediated tumor cell killing in vivo , 1995, European journal of immunology.

[4]  I. Herr,et al.  Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.

[5]  F. Shanahan,et al.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.

[6]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[7]  M. Martínez-Lorenzo,et al.  Doxorubicin‐induced apoptosis in human T‐cell leukemia is mediated by caspase‐3 activation in a Fas‐independent way , 1997, FEBS letters.

[8]  Margot Thome,et al.  Inhibition of death receptor signals by cellular FLIP , 1997, Nature.

[9]  R. Greil,et al.  Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. , 1997, Cancer research.

[10]  O. Yoshida,et al.  Doxorubicin sensitizes human bladder carcinoma cells to Fas‐mediated cytotoxicity , 1997, Cancer.

[11]  M. Parmar,et al.  A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. , 1998, British Journal of Cancer.

[12]  D. Botstein,et al.  Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer , 1998, Nature.

[13]  Lawrence D. True,et al.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder , 1998 .

[14]  F. Mostofi,et al.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. , 1998, The American journal of surgical pathology.

[15]  H. Stein,et al.  ©1999 Cancer Research Campaign Article no. bjoc.1998.0202 , 2022 .

[16]  M. Volm,et al.  Expression of FAS (CD95/APO‐1) and FAS ligand in lung cancer, its prognostic and predictive relevance , 1999, International journal of cancer.

[17]  W. Dalton,et al.  Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation. , 1999, Blood.

[18]  Lee,et al.  Transitional cell carcinoma expresses high levels of Fas ligand in vivo , 1999, BJU international.

[19]  T. Kanematsu,et al.  Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  P. Möller,et al.  CD95 ligand (CD95L) immunohistochemistry: a critical study on 12 antibodies , 2001, Cell Death and Differentiation.

[21]  M. Weller,et al.  Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. , 2001, Cancer research.

[22]  T. Shimada,et al.  Preferential gene transfer to BBN-induced rat bladder tumor by simple instillation of adenoviral vector. , 2001, Urology.

[23]  B. Hoel,et al.  Doxorubicin Pretreatment Sensitizes Prostate Cancer Cell Lines to TRAIL Induced Apoptosis Which Correlates with the Loss of c-FLIP Expression , 2002, Cancer biology & therapy.

[24]  V. Bilim,et al.  Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  T. Eberlein,et al.  Fas (CD95/APO‐1) and Fas ligand expression in normal pancreas and pancreatic tumors , 2002, Cancer.

[26]  A. Lazaris,et al.  Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications , 2002, Urological Research.

[27]  R. Herrmann,et al.  DCR3 locus is a predictive marker for 5‐fluorouracil‐based adjuvant chemotherapy in colorectal cancer , 2002, International journal of cancer.

[28]  L. Owen-Schaub,et al.  Adenoviral Bid Overexpression Induces Caspase-dependent Cleavage of Truncated Bid and p53-independent Apoptosis in Human Non-small Cell Lung Cancers* , 2003, Journal of Biological Chemistry.

[29]  V. Bilim,et al.  Role of IRF-1 and caspase-7 in IFN-gamma enhancement of Fas-mediated apoptosis in ACHN renal cell carcinoma cells. , 2001, International journal of cancer.

[30]  V. Bilim,et al.  Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug‐resistant TCC in vitro , 2003, International journal of cancer.

[31]  V. Bilim,et al.  Role of IRF‐1 and caspase‐7 in IFN‐γ enhancement of Fas‐mediated apoptosis in ACHN renal cell carcinoma cells , 2003 .

[32]  D. Chopin,et al.  Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. , 2003, The American journal of pathology.

[33]  H. Kalthoff,et al.  Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria‐mediated apoptosis , 2004, International journal of cancer.

[34]  V. Bilim,et al.  Adriamycin (ADM) induced apoptosis in Transitional Cell Cancer (TCC) cell lines accompanied by p21 WAF1/CIP1 induction , 2004, Apoptosis.

[35]  A. Suminoe,et al.  mRNA expression of apoptosis-associated genes in infant acute lymphoblastic leukemia: low Fas expression is an independent predictor for poor prognosis , 2004, Leukemia.

[36]  W. Schulz,et al.  Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status. , 2004, Urology.

[37]  V. Bilim,et al.  Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients , 2004, British Journal of Cancer.